OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
GLNYSE67

GLOBE LIFE INC.

Life & Health InsuranceVerified

Globe Life Inc. maintains a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure. The company's liquidity is assessed as medium, with free cash flow of $1.25 billion in FY2025, which supports its operational and investment activities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Globe Life Inc. reported a return on equity (ROE) of 19.44% and a return on assets (ROA) of 3.77% in FY2025. These figures suggest that the company is generating strong returns relative to its equity base but moderate returns relative to its total assets. The company's operating income of $1.27 billion and net income of $1.16 billion reflect its ability to maintain profitability despite the challenges in the insurance sector. Globe Life Inc. operates through three primary segments: life insurance, supplemental health insurance, and investments. The life insurance segment includes traditional whole life and term life insurance products, while the supplemental health insurance segment offers Medicare Supplement and limited-benefit health insurance products. The company's geographic exposure is primarily within the United States, with a focus on domestic insurance markets. The company's revenue concentration is not explicitly disclosed, but its operations are heavily dependent on the U.S. insurance market. The company's growth trajectory is influenced by its strategic focus on expanding its life and health insurance offerings. The outlook for FY2025 indicates a continuation of current trends, with no significant revenue growth expected in the near term. The company's capital expenditure of $142.48 million in FY2025 reflects its investment in infrastructure and technology to support its operations. Globe Life Inc. faces several risk factors, including potential downgrades of its risk-based capital and solvency ratios due to significant downgrades or defaults of issuers in its investment portfolio. The company's investment portfolio contains alternative investments that may be illiquid and volatile, which could negatively affect its investment income and liquidity. The risk of dilution is assessed as low, with a dilution potential of 10.5% based on the difference between basic and diluted shares outstanding. Recent events and filings highlight the company's participation in reinsurance activities to minimize exposure to significant risks and provide additional capacity for future growth. The company also faces regulatory changes, such as the guidance on internal-use software accounting, which may require additional disclosures but is not expected to significantly impact its financial position.

30-day price · GL+15.82 (+11.4%)
Low$135.07High$162.45Close$154.40As of18 May, 00:00 UTC
Profile
CompanyGLOBE LIFE INC.
ExchangeNYSE
TickerGL
CIK0000320335
SICLife Insurance
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryLife & Health Insurance
AI analysis

Business. Globe Life Inc. is an insurance holding company that provides life insurance, supplemental health insurance, and investment products through its subsidiaries, including Globe Life And Accident Insurance Company and American Income Life Insurance Company.

Classification. Globe Life Inc. is classified under the Financials sector, Insurance business sector, and Life & Health Insurance industry with a confidence level of 0.92.

Globe Life Inc. maintains a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure. The company's liquidity is assessed as medium, with free cash flow of $1.25 billion in FY2025, which supports its operational and investment activities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Globe Life Inc. reported a return on equity (ROE) of 19.44% and a return on assets (ROA) of 3.77% in FY2025. These figures suggest that the company is generating strong returns relative to its equity base but moderate returns relative to its total assets. The company's operating income of $1.27 billion and net income of $1.16 billion reflect its ability to maintain profitability despite the challenges in the insurance sector. Globe Life Inc. operates through three primary segments: life insurance, supplemental health insurance, and investments. The life insurance segment includes traditional whole life and term life insurance products, while the supplemental health insurance segment offers Medicare Supplement and limited-benefit health insurance products. The company's geographic exposure is primarily within the United States, with a focus on domestic insurance markets. The company's revenue concentration is not explicitly disclosed, but its operations are heavily dependent on the U.S. insurance market. The company's growth trajectory is influenced by its strategic focus on expanding its life and health insurance offerings. The outlook for FY2025 indicates a continuation of current trends, with no significant revenue growth expected in the near term. The company's capital expenditure of $142.48 million in FY2025 reflects its investment in infrastructure and technology to support its operations. Globe Life Inc. faces several risk factors, including potential downgrades of its risk-based capital and solvency ratios due to significant downgrades or defaults of issuers in its investment portfolio. The company's investment portfolio contains alternative investments that may be illiquid and volatile, which could negatively affect its investment income and liquidity. The risk of dilution is assessed as low, with a dilution potential of 10.5% based on the difference between basic and diluted shares outstanding. Recent events and filings highlight the company's participation in reinsurance activities to minimize exposure to significant risks and provide additional capacity for future growth. The company also faces regulatory changes, such as the guidance on internal-use software accounting, which may require additional disclosures but is not expected to significantly impact its financial position.
Key takeaways
  • Globe Life Inc. maintains a conservative capital structure with a debt-to-equity ratio of 0.44.
  • The company's return on equity of 19.44% indicates strong profitability relative to its equity base.
  • The company's investment portfolio contains alternative investments that may be illiquid and volatile.
  • The company's growth trajectory is influenced by its strategic focus on expanding its life and health insurance offerings.
  • The company's risk of dilution is assessed as low, with a dilution potential of 10.5%.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodFY2025
CurrencyUSD
Revenue$5.99B
Gross profit$1.26B
Operating income$1.27B
Net income$1.16B
R&D
SG&A$302.1M
D&A
SBC$53.4M
Operating cash flow$1.40B
CapEx$142.5M
Free cash flow$1.25B
Total assets$30.81B
Total liabilities$24.84B
Total equity$5.97B
Cash & equivalents
Long-term debt$2.32B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$5.99B$1.16B$1.25B
FY2024$5.78B$1.07B$1.33B
FY2025$5.78B$1.07B$1.33B
FY2023$5.45B$1.27B$970.8M$1.43B
FY2024$5.45B$970.8M$1.43B
PeriodGross %Op %Net %FCF %
FY2025
FY2024
FY2025
FY2023
FY2024
PeriodAssetsEquityCashDebt
FY2025$30.81B$5.97B
FY2024$29.08B$5.31B
FY2025$29.08B$5.31B
FY2023$28.05B$4.49B
FY2024$28.05B$4.49B
PeriodOCFCapExFCFSBC
FY2025$1.40B$142.5M$1.25B$53.4M
FY2024$1.40B$71.0M$1.33B$40.1M
FY2025$1.40B$71.0M$1.33B$40.1M
FY2023$1.48B$49.6M$1.43B$30.7M
FY2024$1.48B$49.6M$1.43B$30.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q3 2025$4.47B$895.2M$923.8M
Q2 2025$2.96B$507.3M$715.1M
Q3 2025
Q1 2025$1.48B$254.6M$420.1M
PeriodGross %Op %Net %FCF %
Q3 2025
Q2 2025
Q3 2025
Q1 2025
PeriodAssetsEquityCashDebt
Q3 2025$30.53B$5.69B
Q2 2025$29.81B$5.42B
Q3 2025$5.42B
Q1 2025$29.71B$5.43B
PeriodOCFCapExFCFSBC
Q3 2025$1.05B$122.0M$923.8M$40.7M
Q2 2025$739.8M$24.7M$715.1M$26.1M
Q3 2025
Q1 2025$431.9M$11.7M$420.1M$12.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$5.48B
Net cash-$2.31B
Current ratio
Debt/Equity0.4
ROA3.8%
ROE19.4%
Cash conversion1.2%
CapEx/Revenue2.4%
SBC/Revenue0.9%
Asset intensity0.0
Dilution ratio-10.5%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Life & Health Insurance · cohort 1 companies
MetricGLActivity
Op margin21.1%21.1% medp25 16.7% · p75 136.5%above median
Net margin19.4%10.4% medp25 5.7% · p75 19.8%above median
Gross margin21.0%21.0% medp25 21.0% · p75 21.0%top quartile
CapEx / revenue2.4%2.4% medp25 2.4% · p75 2.4%top quartile
Debt / equity44.0%48.5% medp25 43.7% · p75 53.3%below median
Observations
IR observations
market data ESG controversies score0.9
market data ESG governance pillar79.6
market data ESG social pillar55.0
market data insider trading score1.0
Source: analysis-pipeline (hybrid)Generated: 2026-05-01 10:11 UTCJob: c2e077a0